Armacokinetic profile. Translation in two advanced BC patients, resulted in no negative effects, confirming preceding observations on the biosafety of CC-17369 MedChemExpress radiotracers depending on the potent GRPR-antagonist [DPhe6 ,LeuNHEt13 ]BBN(6-13) and on GRPR-antagonist radioligands in general. Additionally, it revealed the capacity of [99m Tc]Tc-DB15 to detect a number of metastatic BC lesions, both within the skeleton and in soft tissues, but these findings must be confirmed prospectively inside a dedicated human study. In view of the above, further clinical evaluation appears to be warranted to establish the diagnostic value of [99m Tc]Tc-DB15 in BC, Pc, as well as other GRPR-expressing human malignancies.Supplementary Supplies: The following are obtainable on line at https://www.mdpi.com/article/ 10.3390/cancers13205093/s1, Figure S1: Standard radiochromatogram of HPLC evaluation of [99m Tc]TcDB15 (preclinical); Figure S2: Common radiochromatogram of HPLC analysis of [99m Tc]Tc-DB15 (for sufferers); Figure S3: Whole body scan three h pi of [99m Tc]Tc-DB15 in patient 1 (with anterior and posterior projection); Figure S4: PET/CT 1 h pi of [18 F]FDG in patient 1; Table S1: Numerical biodistribution information for [99m Tc]Tc-DB15 in PC-3 xenograft-bearing SCID mice at 1, 4 and 24 h pi; Table S2: Numerical biodistribution information for [99m Tc]Tc-DB15 in T-47D xenograft-bearing SCID mice at 1, 4 and 24 h pi.Cancers 2021, 13,12 ofAuthor Contributions: Conceptualization, B.A.N., R.M. and T.M.; methodology, B.A.N., A.K., P.K., B.J., B.B., D.I. and T.M.; validation, B.A.N., R.M., R.C., D.I. and T.M.; investigation, B.A.N., A.K., P.K., B.J., B.B., R.C., D.I. and T.M.; resources, R.M., R.C. and T.M.; information curation, P.K., R.M., R.C. and T.M.; writing–original draft preparation, T.M.; writing–review and editing, all co-authors; supervision, B.A.N., R.M., R.C. and T.M.; project administration, R.M., R.C. and T.M.; funding acquisition, R.M., R.C. and T.M. All authors have study and agreed for the published version on the manuscript. Funding: The preclinical study was co-financed by Greece and the European Union (European Regional Development Fund) via the project “NCSRD–INRASTES study activities inside the framework from the national RIS3” (MIS 5002559), implemented below the “Action for the Strategic Development around the Analysis and Technological Sector”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020). Additional support was offered by Siemens AG by means of the project stablishing a Multidisciplinary and Effective Innovation and Entrepreneurship Hub(E-11928). The preparation in the radioligand for the patient study was supported by the CERAD project, financed below Smart Development Operational System 2014020, Priority IV, Measure 4.2. POIR.04.02.004-A001/16. The clinical a part of the study obtained economic assistance in the Poznan University of Medical Sciences (grant No. 502-14-22213550-41147). Institutional Evaluation Board Statement: The animal and patient studies had been carried out as outlined by the suggestions of your Declaration of Helsinki. The animal protocols were approved by the Division of Agriculture and Veterinary Service from the Prefecture of Athens (protocol numbers #1609 for the stability and #1610 for the biodistribution studies, both Ganoderic acid DM Cancer issued on 11 April 2018). The patient study protocol was authorized by the Bioethical Committee with the Poznan University of Health-related Sciences (selection no. 1153 issued on 16 January 2020). Informed Consent Statement: Patients gave th.
